Implementation and Evaluation of an Economic Model for Telestroke: Experience from Virtuall, France

被引:4
作者
Riou-Comte, Nolwenn [1 ]
Mione, Gioia [1 ]
Humbertjean, Lisa [1 ]
Brunner, Arielle [2 ]
Vezain, Arnaud [3 ]
Lavandier, Karine [4 ]
Marchal, Sophie [5 ]
Bracard, Serge [6 ]
Debouverie, Marc [1 ]
Richard, Sebastien [1 ,7 ]
机构
[1] Univ Hosp Nancy, Dept Neurol, Stroke Unit, Nancy, France
[2] Agence Reg Sante, Nancy, France
[3] GCS Telesante Lorraine, Villers Les Nancy, France
[4] Hosp Bar Le Duc, Bar Le Duc, France
[5] Hosp Verdun, Verdun, France
[6] Univ Hosp Nancy, Dept Neuroradiol, Nancy, France
[7] Univ Hosp Nancy, CIC P 1433, INSERM, U1116, Vandoeuvre Les Nancy, France
关键词
telestroke; telemedicine; hub-and-spoke model; health economic model; hospitalization costs; ACUTE ISCHEMIC-STROKE; HEALTH-CARE PROFESSIONALS; COST-EFFECTIVENESS; MANAGEMENT; NETWORKS; OUTCOMES;
D O I
10.3389/fneur.2017.00613
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Background: Telestroke is recognized as a safe and time-efficient way of treating stroke patients. However, admission centers (spokes) are subject to financial charges which can make them reluctant to join the system. We implemented and assessed an economic model supporting our telestroke system, Virtuall, France, which includes one expert center (hub) and six spokes. Methods: The model is based on payment for the expertise provided by the hub, distribution of charges related to telemedicine according to the fees perceived by the spokes, and transfer of patients between the spokes and the hub. We performed a cost-benefit analysis for all patients included in Virtuall from January 2014 to December 2015 to assess the economic balance in each center. Results: 321 patients were prospectively included in the study. Application of the economic model resulted in overall financial balance with funding of a dedicated medical service in the hub, and reduced costs directly related to telestroke by an average of 10% in the spokes. The conditions generating the highest costs for the spokes were: a patient returning from the hub for re-hospitalization (mean cost of $1,995/patient); management of patients treated by intravenous thrombolysis without transfer to the hub (mean cost of $2,075/patient). The most favorable financial condition for the spokes remained simple transfer of patients to the hub and no return (mean cost of $329/patient). Conclusion: We describe an economic model which can be applied to any telestroke system to ensure the optimal balance between hub and spoke centers.
引用
收藏
页数:9
相关论文
共 50 条
[41]   Economic evaluation in chronic pain: a systematic review and de novo flexible economic model [J].
Sullivan, W. ;
Hirst, M. ;
Beard, S. ;
Gladwell, D. ;
Fagnani, F. ;
Lopez Bastida, J. ;
Phillips, C. ;
Dunlop, W. C. N. .
EUROPEAN JOURNAL OF HEALTH ECONOMICS, 2016, 17 (06) :755-770
[42]   Implementation of Pharmaceutical Practice Guidelines by a Project Model Based Clinical and Economic Impact [J].
Mahmoudi, Laleh ;
Karamikhah, Razieh ;
Mahdavinia, Azadeh ;
Samiei, Hasan ;
Petramfar, Peyman ;
Niknam, Ramin .
MEDICINE, 2015, 94 (42) :e1744
[43]   Health economic evaluation of outpatient management of fibromyalgia patients and the costs avoided by diagnosing fibromyalgia in France [J].
Lamotte, M. ;
Maugars, Y. ;
Le Lay, K. ;
Taieb, C. .
CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2010, 28 (06) :S64-S70
[44]   Health economic evaluation of Human Papillomavirus vaccines in women from Venezuela by a lifetime Markov cohort model [J].
Esteban Bardach, Ariel ;
Ulises Garay, Osvaldo ;
Calderon, Maria ;
Pichon-Riviere, Andres ;
Augustovski, Federico ;
Garcia Marti, Sebastin ;
Cortinas, Paula ;
Gonzalez, Marino ;
Naranjo, Laura T. ;
Alberto Gomez, Jorge ;
Enzo Caporale, Joaquin .
BMC PUBLIC HEALTH, 2017, 17 :1-15
[45]   Economic Evaluation of Umeclidinium/Vilanterol versus Umeclidinium or Salmeterol in Symptomatic Non-Exacerbating Patients with COPD from a UK Perspective Using the GALAXY Model [J].
Shukla, Soham ;
Shah, Dhvani ;
Martin, Alan ;
Risebrough, Nancy A. ;
Kendall, Robyn ;
Vogelmeier, Claus F. ;
Boucot, Isabelle ;
Tombs, Lee ;
Bjermer, Leif ;
Jones, Paul W. ;
Kerwin, Edward ;
Compton, Chris ;
Maltais, Francois ;
Lipson, David A. ;
Ismaila, Afisi .
INTERNATIONAL JOURNAL OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE, 2021, 16 :3105-3118
[46]   Systematic review of the economic evaluation model of assisted reproductive technology [J].
Si, Yuxin ;
Tan, Tao ;
Pu, Kexue .
HEALTH ECONOMICS REVIEW, 2024, 14 (01)
[47]   Model concept of the health economic evaluation of low-dose CT lung cancer screening in Hungary [J].
Voko Zoltan ;
Barra Magdolna ;
Molnar Anett ;
Kerpel-Fronius Anna ;
Bajzik Gabor ;
Horvath Ildiko ;
Moizs Mariann ;
Nagy Balazs .
ORVOSI HETILAP, 2017, 158 (25) :963-975
[48]   Health economic evaluation of the Lund Integrated Medicines Management Model (LIMM) in elderly patients admitted to hospital [J].
Ghatnekar, Ola ;
Bondesson, Asa ;
Persson, Ulf ;
Eriksson, Tommy .
BMJ OPEN, 2013, 3 (01)
[49]   A model-based economic evaluation of four newborn screening strategies for cystic fibrosis in Flanders, Belgium [J].
Schmidt, Masja ;
Werbrouck, Amber ;
Verhaeghe, Nick ;
De Wachter, Elke ;
Simoens, Steven ;
Annemans, Lieven ;
Putman, Koen .
ACTA CLINICA BELGICA, 2020, 75 (03) :212-220
[50]   Social impact bonds and the tactics of feasibility: experience from Chile, Colombia and France [J].
Pellizzari, Mathilde ;
Muniesa, Fabian .
INTERNATIONAL PUBLIC MANAGEMENT JOURNAL, 2023, 26 (03) :357-375